Arabic Arabic English English French French German German
dark

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

Arsenal Biosciences, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio to discover and advance next-generation T cell therapies for the treatment of solid tumors. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Travere Therapeutics Provides Corporate Update and 2022 Outlook

Next Post

TISSIUM Appoints Ruth Krestin as Vice President of Portfolio Strategy

Related Posts
Total
0
Share